NO943893L - Galantaminderivater, en fremgangsmåte for fremstilling samt deres anvendelse som medikamenter - Google Patents

Galantaminderivater, en fremgangsmåte for fremstilling samt deres anvendelse som medikamenter

Info

Publication number
NO943893L
NO943893L NO943893A NO943893A NO943893L NO 943893 L NO943893 L NO 943893L NO 943893 A NO943893 A NO 943893A NO 943893 A NO943893 A NO 943893A NO 943893 L NO943893 L NO 943893L
Authority
NO
Norway
Prior art keywords
hydrogen
medicaments
preparation
alkylaminocarbonyl
alkyl
Prior art date
Application number
NO943893A
Other languages
English (en)
Other versions
NO310415B1 (no
NO943893D0 (no
Inventor
Jr Raymond Walter Kosley
Larry Davis
Veronica Taberna
Original Assignee
Hoechst Roussel Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Roussel Pharma filed Critical Hoechst Roussel Pharma
Publication of NO943893D0 publication Critical patent/NO943893D0/no
Publication of NO943893L publication Critical patent/NO943893L/no
Publication of NO310415B1 publication Critical patent/NO310415B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO19943893A 1993-10-15 1994-10-14 Galantaminderivater, farmasöytisk sammensetning omfattende samme samt deres anvendelse for fremstilling av et medikament NO310415B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/137,440 US6323195B1 (en) 1993-10-15 1993-10-15 Galanthamine derivatives as acetylcholinesterase inhibitors

Publications (3)

Publication Number Publication Date
NO943893D0 NO943893D0 (no) 1994-10-14
NO943893L true NO943893L (no) 1995-04-18
NO310415B1 NO310415B1 (no) 2001-07-02

Family

ID=22477446

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19943893A NO310415B1 (no) 1993-10-15 1994-10-14 Galantaminderivater, farmasöytisk sammensetning omfattende samme samt deres anvendelse for fremstilling av et medikament

Country Status (23)

Country Link
US (2) US6323195B1 (no)
EP (2) EP1020470A3 (no)
JP (1) JP2664344B2 (no)
KR (1) KR0169114B1 (no)
CN (1) CN1039911C (no)
AT (1) ATE212348T1 (no)
AU (1) AU696249B2 (no)
CA (1) CA2118174C (no)
CZ (1) CZ287071B6 (no)
DE (1) DE69429708T2 (no)
DK (1) DK0653427T3 (no)
EG (1) EG20472A (no)
ES (1) ES2171428T3 (no)
FI (1) FI108723B (no)
IL (1) IL111274A (no)
NO (1) NO310415B1 (no)
NZ (1) NZ264683A (no)
PL (1) PL177730B1 (no)
PT (1) PT653427E (no)
RO (1) RO114133B1 (no)
RU (1) RU2114850C1 (no)
TW (1) TW363969B (no)
ZA (1) ZA948062B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US7939522B1 (en) 1998-11-23 2011-05-10 Bonnie M Davis Dosage formulations for acetylcholinesterase inhibitors
AU775914B2 (en) 1998-12-24 2004-08-19 Janssen Pharmaceutica N.V. Controlled release galantamine composition
US8603546B2 (en) * 1999-01-11 2013-12-10 Herbaceuticals Inc. Herbal supplement for increased muscle strength and endurance for athletes
AU2504200A (en) * 1999-01-11 2000-08-01 Atanas Russinov Djananov Herbal supplement for increased muscle strength and endurance for athletes
DE69913138T2 (de) * 1999-03-31 2004-08-26 Eisai Co., Ltd. Stabilisierte zusammensetzung mit nootropen wirkstoffen
DK1237539T3 (da) * 1999-10-26 2006-02-27 Janssen Pharmaceutica Nv Oral oplösning indeholdende galanthamin og et södemiddel
AU780012B2 (en) * 1999-12-10 2005-02-24 Bonnie Davis Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
JP2003529602A (ja) 2000-03-31 2003-10-07 ザノヒェミア・ファルマツォイティカ・アーゲー ガランタミンの新規誘導体および類似体
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
CA2552114A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
JPWO2006004201A1 (ja) * 2004-07-01 2008-04-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 神経再生促進剤
WO2006124584A2 (en) * 2005-05-13 2006-11-23 Alza Corporation Multilayer drug delivery system with barrier against reservoir material flow
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
EP1777222A1 (en) 2005-09-22 2007-04-25 Galantos Pharma GmbH Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
JP2009508903A (ja) * 2005-09-22 2009-03-05 ガラントス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 認知障害を伴う疾患の治療に用いるための脳血液関門透過性が改善されたコリン作用増強剤
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
WO2007035941A2 (en) * 2005-09-23 2007-03-29 Alza Corporation Transdermal galantamine delivery system
JP5504253B2 (ja) 2008-04-14 2014-05-28 ニューロダイン ライフ サイエンス インコーポレイテッド ヒトの脳疾患の治療のためのプロドラッグとしてのガランタミン誘導体
MX2012000939A (es) * 2009-07-23 2012-06-08 Shire Llc Profarmacos de peptidos y aminoacidos de galantamina y usos de los mismos.
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
EP3628315A1 (en) 2018-09-28 2020-04-01 Université de Caen Normandie Combination of acetylcholinesterase inhibitor and 5-ht4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases
CN113292420A (zh) * 2021-05-27 2021-08-24 神隆医药（常熟）有限公司 加兰他敏中间体原料2-溴-5-羟基-4-甲氧基苯甲酸回收方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL122665B1 (en) 1978-11-21 1982-08-31 Edinen Zentar Chim Process for preparing novel dienones of narvedine type and their derivatives
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
KR100195399B1 (ko) * 1987-05-04 1999-06-15 보니데이비스 알쯔하이머 병 치료용 의약
NL8800350A (nl) 1988-02-12 1989-09-01 Stichting Biomedical Research Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
EP0515301A3 (en) 1991-05-14 1993-06-16 Ernir Snorrason Improvements in benzodiazepine treatment by cholinesterterase inhibitors
US5153193A (en) 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US5231093A (en) * 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs

Also Published As

Publication number Publication date
RU2114850C1 (ru) 1998-07-10
CZ287071B6 (en) 2000-08-16
RO114133B1 (ro) 1999-01-29
JP2664344B2 (ja) 1997-10-15
DE69429708T2 (de) 2002-08-29
EP1020470A3 (en) 2000-07-26
CN1039911C (zh) 1998-09-23
IL111274A0 (en) 1994-12-29
KR0169114B1 (ko) 1999-01-15
EG20472A (en) 1999-05-31
NO310415B1 (no) 2001-07-02
EP1020470A2 (en) 2000-07-19
ES2171428T3 (es) 2002-09-16
DK0653427T3 (da) 2002-04-15
EP0653427B1 (en) 2002-01-23
CA2118174A1 (en) 1995-04-16
ZA948062B (en) 1995-06-06
KR950011443A (ko) 1995-05-15
TW363969B (en) 1999-07-11
CN1111245A (zh) 1995-11-08
RU94036448A (ru) 1996-09-10
IL111274A (en) 2000-11-21
US5777108A (en) 1998-07-07
PL177730B1 (pl) 2000-01-31
PT653427E (pt) 2002-06-28
JPH07188240A (ja) 1995-07-25
NO943893D0 (no) 1994-10-14
ATE212348T1 (de) 2002-02-15
FI108723B (fi) 2002-03-15
AU7581494A (en) 1995-05-04
AU696249B2 (en) 1998-09-03
CA2118174C (en) 2000-01-18
FI944821A (fi) 1995-04-16
CZ254694A3 (en) 1995-09-13
FI944821A0 (fi) 1994-10-13
EP0653427A1 (en) 1995-05-17
DE69429708D1 (de) 2002-03-14
NZ264683A (en) 1998-03-25
PL305456A1 (en) 1995-04-18
US6323195B1 (en) 2001-11-27

Similar Documents

Publication Publication Date Title
NO943893L (no) Galantaminderivater, en fremgangsmåte for fremstilling samt deres anvendelse som medikamenter
NO307463B1 (no) Galantaminderivater, en fremgangsmõte for fremstilling samt deres anvendelse som medikamenter
ZA932168B (en) Naphthylalkylamines, process for preparing them and pharmaceutical compositions containing them
AU7350694A (en) Remedy for nervous diseases
AU4616893A (en) New benzopyran compounds, process for their preparation and the pharmaceutical compositions which contain them
NO943895L (no) Galantaminderivater, en fremgangsmåte for fremstilling samt deres anvendelse som medikamenter
CA2017535A1 (en) Antispasmodic agents
DK0505778T3 (da) Derivater af imidazol-2-oner samt fremgangsmåde til fremstilling deraf
AU5473596A (en) New indole, indazole benzisoxazole compounds, their process of preparation and the pharmaceutical compositions which contain them
HU9503775D0 (en) Benzene derivative useful for ischemic diseases
DK0570850T3 (da) Benzo(b)thiophen-3-yl-piperaziner, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler
DK0614887T3 (da) Indolsulfonamider som antitumormidler

Legal Events

Date Code Title Description
MK1K Patent expired